Similar to γ-secretase, the enzyme protein kinase C (PKC) also encountered some inconsistencies in its handling when early studies suggested the pharmacological activation of PKC as a target for the treatment of AD [47,48]. This evidence concerns the gene PRRT2 and Alzheimer disease.